Home/Investors/Boxer Capital

Boxer Capital

Biotech Investor · 2 portfolio companies

Portfolio

2

Combined Value

$1.1B

Focus Areas

7

Top Stage

Phase 1

Investment Focus

Neurology Rare Genetic Diseases Neuromuscular Rare Diseases Muscular Dystrophy Genetic Disorders Hematology

Portfolio Companies

Company	Stage	Valuation	Focus
Design Therapeutics	Phase 1	$635.8M	Neurology, Rare Genetic Diseases
Fulcrum Therapeutics	Phase 3	$450.9M	Rare Diseases, Muscular Dystrophy

Frequent Co-Investors

Public market investors1 shared Fidelity Management & Research Company1 shared Cormorant Asset Management1 shared New Enterprise Associates (NEA)1 shared Redmile Group1 shared SR One (GSK's venture arm)1 shared Quan Capital1 shared Entities associated with RA Capital1 shared